Molecular pathology of non-small-cell lung cancer

Respiration

Volumn 72, Issue 3, 2005, Pages 313-330

  Breuer, R H J ^a   Postmus, P E ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinogenesis; Lung cancer; Molecular pathology; Non small cell lung cancer; Oncogenes; Tumor suppressor genes

Indexed keywords

BETA CATENIN; CELL NUCLEUS RECEPTOR; CYCLIN D; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; PROSTAGLANDIN SYNTHASE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SEMAPHORIN; SEMAPHORIN 3F; SURVIVIN; TELOMERASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER SCREENING; CELL INVASION; CHROMOSOME 3P; CHROMOSOME ANALYSIS; ENZYME ACTIVATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; GROWTH STIMULATION; HEALTH PROGRAM; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; ONCOGENE MYC; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 3; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MICROSATELLITE REPEATS; ONCOGENES; PROTEOMICS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 22144447535     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085376     Document Type: Review

References (198)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.
3. Janssen-Heijnen ML, Coebergh JW: The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-258.
4. Auerbach O, Hammond EC, Garfinkel L: Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 1979;300:381-385.
5. Loeb LA: A mutator phenotype in cancer. Cancer Res 2001;61:3230-3239.
6. Li D, Firozi PF, Wang LE, Bosken CH, Spitz MR, Hong WK, Wei Q: Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: A case-control analysis. Cancer Res 2001;61:1445-1450.
7. Shen H, Spitz MR, Qiao Y, Guo Z, Wang LE, Bosken CH, et al: Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer 2003;107:84-88.
8. Wei Q, Cheng L, Hong WK, Spitz MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996;56:4103-4107.
9. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764-1772.
10. Wu X, Gu J, Amos CI, Jiang H, Hong WK, Spitz MR: A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer 1998;83:1118-1127.
11. Hecht SS: Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-469.
12. Houlston RS: CYP1A1 polymorphisms and lung cancer risk: A meta-analysis. Pharmacogenetics 2000;10:105-114.
13. Houlston RS: Glutathione S-transferase M1 status and lung cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 1999;8:675-682.
14. Chang JW, Chen YC, Chen CY, Chen JT, Chen SK, Wang YC: Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clin Cancer Res 2000;6:1639-1646.
15. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lahti M, Seruca R, et al: Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993;53:5853-5855.
16. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1994;91:9871-9875.
17. Rosell R, Pifarre A, Monzo M, Astudillo J, Lopez-Cabrerizo MP, Calvo R, et al: Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 1997;74:330-334.
18. Miozzo M, Sozzi G, Musso K, Pilotti S, Incarbone M, Pastorino U, et al: Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 1996;56:2285-2288.
19. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, et al: Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987;330:578-581.
20. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH: Sequential molecular genetic changes in lung cancer development. Oncogene 1995;11:2591-2598.
21. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, et al: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:643-650.
22. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-1960.
23. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, et al: Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 1994;9:1599-1604.
24. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, et al: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992;7:445-449.
25. Knudson AG Jr: The ninth Gordon Hamilton-Fairley memorial lecture. Hereditary cancers: Clues to mechanisms of carcinogenesis. Br J Cancer 1989;59:661-666.
26. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
27. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
29. Gao HG, Chen JK, Stewart J, Song B, Rayappa C, Whong WZ, et al: Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis 1997;18:473-478.
30. Toyooka S, Tsuda T, Gazdar AF: The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-239.
31. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, et al: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993;53:4817-4822.
32. Boers JE, ten Velde GP, Thunnissen FB: P53 in squamous metaplasia: A marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med 1996;153:411-416.
33. Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, et al: p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998;4:1609-1618.
34. Breuer RH, Snijders PJ, Sutedja TG, Linden H, Risse EK, Meijer CJ, et al: Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. Lung Cancer 2003;40:165-172.
35. Fontanini G, Vignati S, Bigini D, Merlo GR, Ribecchini A, Angeletti CA, et al: Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol 1994;174:23-31.
36. Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla C, et al: Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 2003;9:2195-2203.
37. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H: p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma. Cancer 1999;85:341-347.
38. Li ZH, Zheng J, Weiss LM, Shibata D: c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144: 303-309.
39. Ponticiello A, Barra E, Giani U, Bocchino M, Sanduzzi A: p53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: A prospective study. Eur Respir J 2000;15:547-552.
40. Rusch V, Klimstra D, Linkov I, Dmitrovsky E: Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-1372.
41. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, et al: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992;52:6079-6082.
42. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:1989-1997.
43. Walker C, Dixon GR, Myskow M: Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol 1995;176:319-320.
44. Zheng J, Shu Q, Li ZH, Tsao JI, Weiss LM, Shibata D: Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. Am J Pathol 1994;145:1444-1449.
45. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
46. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241:353-357.
47. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, et al: Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993;8:1913-1919.
48. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
49. Belinsky SA, Nikula KT, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-11896.
50. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C: Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999;5: 243-250.
51. Brambilla E, Moro D, Gazzeri S, Brambilla C: Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999;188:351-360.
52. Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M: Differential frequen-cies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-3229.
53. Lamy A, Sesboue R, Bourguignon J, Dautreaux B, Metayer J, Frebourg T, et al: Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high-risk patients without invasive cancer. Int J Cancer 2002;100:189-193.
54. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999;96:12754-12759.
55. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E: Mechanisms of p16INK4A inactivation in nonsmall-cell lung cancers. Oncogene 1998;16:497-504.
56. Esteller M, Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
57. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-168.
58. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, et al: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001;84:1372-1376.
59. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, et al: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300.
60. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS: Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-2476.
61. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al: Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-2093.
62. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999;125:61-70.
63. Schauer IE, Siriwardana S, Langan TA, Sclafani RA: Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994;91:7827-7831.
64. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, et al: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
65. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, et al: Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-5582.
66. Otterson GA, Xiao GH, Geradts J, Jin F, Chen WD, Niklinska W, Kaye FJ, Yeung RS: Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl Cancer Inst 1998;90:426-432.
67. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, et al: Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771-13776.
68. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al: The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002;21:1381-1390.
69. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20:1509-1518.
70. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
71. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319.
72. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, et al: Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-2368.
73. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992;17: 427-433.
74. Toulouse A, Morin J, Dion PA, Houle B, Bradley WE: RARbeta2 specificity in mediating RA inhibition of growth of lung cancer-derived cells. Lung Cancer 2000;28:127-137.
75. Berard J, Laboune F, Mukuna M, Masse S, Kothary R, Bradley WE: Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J 1996;10:1091-1097.
76. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, et al: Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 1997;89:624-629.
77. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61: 249-255.
78. Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, et al: Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: Results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003;95:206-214.
79. Martinet N, Alla F, Farre G, Labib T, Drouot H, Vidili R, et al: Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res 2000;60:2869-2875.
80. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, et al: Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 1999;91:1059-1066.
81. Soria JC, Xu X, Liu DD, Lee JJ, Kurie J, Morice RC, et al: Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 2003;95:165-168.
82. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, et al: N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973-2979.
83. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD: β-Carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutr 1995;62(6 Suppl): 1431S-1438S.
84. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-1155.
85. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD: Neuropilin is a semaphorin III receptor. Cell 1997;90:753-762.
86. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E: Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336-347.
87. Brambilla E, Constantin B, Drabkin H, Roche J: Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. Am J Pathol 2000;156:939-950.
88. Vermeulen S, Van Marck V, Van Hoorde L, Van Roy F, Bracke M, Mareel M: Regulation of the invasion suppressor function of the cadherin/catenin complex. Pathol Res Pract 1996; 192:694-707.
89. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM: Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001;54:391-395.
90. Retera JM, Leers MP, Sulzer MA, Theunissen PH: The expression of beta-catenin in non-small-cell lung cancer: A clinicopathological study. J Clin Pathol 1998;51:891-894.
91. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-430.
92. Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, et al: The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002;277:31014-31019.
93. Ito A, Okada M, Uchino K, Wakayama T, Koma Y, Iseki S, et al: Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinoma. Lab Invest 2003;83:1175-1183.
94. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, et al: Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003;107:53-59.
95. Uchino K, Ito A, Wakayama T, Koma Y, Okada T, Ohbayashi C, et al: Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. Cancer 2003;98:1002-1007.
96. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
97. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-355.
98. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
99. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD: Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894-4906.
100. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, et al: Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998;58:509-511.
101. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998;17:1557-1565.
102. Hosoya Y, Gemma A, Seike M, Kurimoto F, Uematsu K, Hibino S, et al: Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer 1999;25:87-93.
103. Kohno T, Takahashi M, Manda R, Yokota J: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosom Cancer 1998;22:152-156.
104. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al: PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-479.
105. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-1184.
106. Torres J, Navarro S, Rogla I, Ripoll F, Lluch A, Garcia-Conde J, et al: Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer 2001;37:114-121.
107. Chun KH, Kosmeder JW, Sun S, Pezzuto JM, Lotan R, Hong WK, Lee HY: Effects of deguelin on the phosphatidylinositol 3-kinase/ Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95:291-302.
108. Wang Y, Minoshima S, Shimizu N: Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn J Hum Genet 1993;38: 399-406.
109. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
110. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL: ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 2001;61:6583-6591.
111. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29(1 suppl 4):3-14.
112. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787-1793.
113. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, et al: Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002;8:734-744.
114. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53(10 suppl):2379-2385.
115. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990;50:7077-7080.
116. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al: The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516.
117. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L, Narayanan R: HER-2/neu expression in archival non-small cell lung carcinomas using PDA-approved Hercep test. Anticancer Res 2000;20:2091-2096.
118. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, et al: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 1989;49:4968-4971.
119. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, et al: The role of HER-2/neu expression on the survival of patients with lung cancer: A systematic review of the literature. Br J Cancer 2003;89:959-965.
120. Hilbe W, Dlaska M, Duba HC, Dirnhofer S, Eisterer W, Oberwasserlechner F, et al: Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: Comparison with immunohistochemistry and clinico-pathological features. Int J Oncol 2003;23:1121-1126.
121. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935.
122. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, et al: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-5741.
123. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T: K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep 2001;8:889-892.
124. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S: Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-1027.
125. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y: Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69:72-77.
126. Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, et al: Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991;51:6346-6350.
127. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001;19:448-457.
128. Broers JL, Viallet J, Jensen SM, Pass H, Travis WD, Minna JD, et al: Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 1993;9:33-43.
129. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al: High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997;89:1609-1615.
130. Hara H, Yamashita K, Shinada J, Yoshimura H, Kameya T: Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 2001;34:219-226.
131. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, et al: Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895-902.
132. Kumaki F, Kawai T, Hiroi S, Shinomiya N, Ozeki Y, Ferrans VJ, et al: Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001;32:188-195.
133. Xinarianos G, Scott FM, Liloglou T, Prime W, Callaghan J, Gosney JR, et al: Telomerase activity in non-small cell lung carcinomas correlates with smoking status. Int J Oncol 1999; 15:961-965.
134. Shibuya K, Fujisawa T, Hoshino H, Baba M, Saitoh Y, Iizasa T, et al: Increased telomerase activity and elevated hTERT mRNA expression during multistage carcinogenesis of squamous cell carcinoma of the lung. Cancer 2001;92:849-855.
135. Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, et al: Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997;57:2373-2377.
136. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al: The RNA component of human telomerase. Science 1995;269: 1236-1241.
137. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795.
138. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68.
139. Steenbergen RD, Kramer D, Meijer CJ, Walboomers JM, Trott DA, Cuthbert AP, et al: Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J Natl Cancer Inst 2001;93: 865-872.
140. Snijders PJ, Breuer RH, Sutedja TG, Egging M, Voorhorst FJ, Steenbergen RD, et al: Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ). Int J Cancer 2004;109:412-417.
141. Marchetti A, Bertacca G, Buttitta F, Chella A, Quattrocolo G, Angeletti CA, et al: Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 1999;5:2077-2081.
142. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR: hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:2883-2889.
143. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al: Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-128.
144. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
145. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
146. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
147. Apte SS, Mattei MG, Olsen BR: Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics 1995;26:592-594.
148. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-2466.
149. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.
150. Chen Y, Sato M, Fujimura S, Endo C, Sakurada A, Aikawa H, et al: Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res 1999;19:1351-1356.
151. Walker C, Robertson L, Myskow M, Dixon G: Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 1995;72:164-169.
152. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, et al: Role of Bcl-2 as a prognostic factor for survival in lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64.
153. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, et al: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997;15:2858-2865.
154. Tock B, Zwiebel JA, Schoenfeldt M: Clinical trials referral resource. Current clinical trials of G3139. Oncology (Huntingt) 2003;17: 1244-1258.
155. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
156. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-2223.
157. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, et al: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-626.
158. Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 2002;128:554-560.
159. Ikehara M, Oshita F, Kameda Y, Ito H, Ohgane N, Suzuki R, Saito H, Yamada K, Noda K, Mitsuda A: Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 2002;9:835-838.
160. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-2104.
161. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
162. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS: Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002;94:1023-1031.
163. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
164. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-867.
165. Takahashi T, Kozaki K, Yatabe Y, Achiwa H, Hida T: Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 2002;21:177-181.
166. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
167. El Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL: Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: The impact of a high-fat diet. Cancer Res 1999;59: 1400-1403.
168. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al: Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997;18:795-799.
169. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
170. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
171. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
172. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ: Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 2003;40:33-44.
173. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-2650.
174. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-146.
175. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al: Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br J Cancer 2003;88:1687-1692.
176. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 1997;89:881-886.
177. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, et al: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-563.
178. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
179. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13: 9-22.
180. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580.
181. Shibusa T, Shijubo N, Abe S: Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 1998;4:1483-1487.
182. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, et al: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-1273.
183. Volm M, Koomagi R, Mattern J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-68.
184. Ohta Y, Watanabe Y, Murakami S, Oda M, Hayashi Y, Nonomura A, et al: Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 1997;76:1041-1045.
185. Fontanini G, Calcinai A, Boldrini L, Lucchi M, Mussi A, Angeletti CA, et al: Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 1999;6:813-817.
186. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, et al: Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000;6:1616-1625.
187. Sporn MB: The war on cancer. Lancet 1996;347:1377-1381.
188. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
189. Kanno N, Nonomura N, Miki T, Kojima Y, Takahara S, Nozaki M, et al: Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line. J Urol 1998;159:586-590.
190. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42.
191. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, et al: Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001;159:1231-1238.
192. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
193. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789.
194. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al: Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-2205.
195. Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, et al: Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99:12357-12362.
196. Li C, Chen Z, Xiao Z, Wu X, Zhan X, Zhang X, et al: Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 2003;309:253-260.
197. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, et al: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-439.
198. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS: Discovery of distinct protein profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-279.